Interest and depreciation leave Wanbury with Rs 3.24 cr profit
Standalone operating margin was 9.81%, while Rs 7.97 cr of interest absorbed nearly half of operating profit.
Filed 11 Aug 2026, 20:44 IST · after market close · WANBURY (WANBURY)
Key takeaways
- Interest of Rs 7.97 cr and depreciation of Rs 4.04 cr reduced Rs 16.24 cr of operating profit to Rs 4.59 cr before tax.
- Standalone net profit was Rs 3.24 cr after a 29.31% tax rate, with other income contributing only Rs 0.36 cr.
- Management said Wanbury plans four commercial launches of new molecules each year from FY27.
Operating profit narrowed sharply by below-the-line costs
Wanbury generated Rs 16.24 cr of operating profit from Rs 165.58 cr of standalone revenue in Q1FY27. Interest of Rs 7.97 cr and depreciation of Rs 4.04 cr left only Rs 4.59 cr as profit before tax. The resulting Rs 3.24 cr net profit came after Rs 1.34 cr of tax.
Earnings quality was not reliant on other income
Other income was Rs 0.36 cr, so it was not the main source of the quarter's pre-tax profit. The more significant drag came from financing and depreciation charges, which together absorbed a large part of operating profit. The standalone operating margin was 9.81%.
Management points to a wider product and capacity pipeline
Management said Wanbury plans four commercial launches of new molecules each year from FY27 and is targeting a patented-molecule supply chain beyond FY29-30. The presentation said existing sites have potential for 600 KL of future reactor capacity. Management also said the formulations business is targeting profitability break-even in FY26 and sustainable profitability from FY27 onwards.
Results were filed after market close
Wanbury filed these standalone Q1FY27 results after market close on 11 Aug 2026. No post-results stock reaction is covered because the filing was too recent.
Q1FY27 at a glance
Standalone figures as filed with NSE — filed ahead of third-party databases, not yet independently cross-checked.
| Line item | Q1FY27 |
|---|---|
| Revenue | ₹166 cr |
| Other income | ₹0 cr |
| Expenses | ₹149 cr |
| Operating profit | ₹16 cr |
| Operating margin (%) | 9.81% |
| Interest | ₹8 cr |
| Depreciation | ₹4 cr |
| Profit before tax | ₹5 cr |
| Tax | ₹1 cr |
| Net profit | ₹3 cr |
| EPS (₹) | ₹0.93 |
What management said
From the company’s own investor presentation. Each point is checked against the source document before it appears here.
Guidance & outlook
- Wanbury plans four commercial launches of new molecules each year from FY27.
- Wanbury targets a patented-molecule supply chain beyond FY29-30.
- The formulations business aims to achieve profitability break-even in FY26 through scale and cost management.
- Wanbury plans to deliver sustainable profitability from FY27 onwards.
Expansion
- Existing sites have potential for future reactor capacity of 600 KL.
- The formulations business plans expansion into newer attractive regions.
- Wanbury plans to increase its field force in existing regions.
New products
- Wanbury commercialised an anaesthetic in Q4FY26.
New initiatives
- Wanbury commercialised an anaesthetic in Q4FY26 and has a pipeline of four molecules each year.
- Wanbury is launching chronic and speciality products in cardiology and diabetes.
Competition
- Wanbury estimates its sertraline market share at approximately 30%.
What to watch
- Whether operating margin holds above 9.81%.
- Whether interest stays below Rs 7.97 cr as operating profit scales.
- Progress on management's plan for four commercial launches of new molecules each year from FY27.